Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

PTPN11 inhibitor

DRUG CLASS:

PTPN11 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BMS-986466 Sensitive: C2 – Inclusion Criteria BMS-986466 Sensitive : C2	BMS-986466 Sensitive: C2 – Inclusion Criteria BMS-986466 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RMC-4630 Sensitive: C2 – Inclusion Criteria RMC-4630 Sensitive : C2	RMC-4630 Sensitive: C2 – Inclusion Criteria RMC-4630 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ERAS-007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ERAS-007 + ERAS-601 Sensitive : C2	ERAS-007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ERAS-007 + ERAS-601 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	glecirasib + JAB-3312 Sensitive: C2 – Inclusion Criteria glecirasib + JAB-3312 Sensitive : C2	glecirasib + JAB-3312 Sensitive: C2 – Inclusion Criteria glecirasib + JAB-3312 Sensitive : C2
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
NF1 mutation	Sarcoma	NF1 mutation	Sarcoma	RMC-4630 Sensitive: C4 – Case Studies RMC-4630 Sensitive : C4	RMC-4630 Sensitive: C4 – Case Studies RMC-4630 Sensitive : C4
BRAF mutation	Solid Tumor	BRAF mutation	Solid Tumor	ERAS-601 Sensitive: C4 – Case Studies ERAS-601 Sensitive : C4	ERAS-601 Sensitive: C4 – Case Studies ERAS-601 Sensitive : C4
EML4-ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4